CAR-T Cell Therapy in China
5+ FDA-equivalent CAR-T products approved. World-class immunotherapy for leukemia, lymphoma, and multiple myeloma at 40-60% lower cost than the US.
Free CAR-T Consultation View Products
5+ FDA-equivalent CAR-T products approved. World-class immunotherapy for leukemia, lymphoma, and multiple myeloma at 40-60% lower cost than the US.
Free CAR-T Consultation View ProductsChina has become a global powerhouse in CAR-T cell therapy development and commercialization.
CD19-targeted CAR-T for relapsed/refractory large B-cell lymphoma. Fosun Kite localization of Kite/Gilead technology.
CD19-targeted CAR-T developed by JW Therapeutics. Approved for relapsed/refractory large B-cell lymphoma.
BCMA-targeted CAR-T for relapsed/refractory multiple myeloma. Developed by Legend Biotech with Johnson & Johnson partnership.
CLDN18.2-targeted CAR-T for gastric and gastroesophageal junction cancer — a world-first solid tumor CAR-T from Carsgen Therapeutics.
CD19-targeted CAR-T for follicular lymphoma. Innovent / Roche collaboration with global development potential.
Allogeneic (off-the-shelf) BCMA CAR-T for multiple myeloma. Eliminates need for patient-specific manufacturing.
CAR-T therapy is typically indicated for patients who have:
⚠️ Important: Eligibility must be confirmed by a hematologist/oncologist after reviewing your complete medical history, imaging, and pathology reports. Request a free eligibility assessment →
Same technology, dramatically different pricing.
| Product | Target | China Price | US Price | EU Price | Your Savings |
|---|---|---|---|---|---|
| Yescarta | CD19 / Lymphoma | $165,000 | $373,000 | €320,000 | Save 56% |
| Fucaso | BCMA / Myeloma | $160,000 | $465,000 | €390,000 | Save 66% |
| Relma-cel | CD19 / Lymphoma | $178,000 | N/A | N/A | China Exclusive |
| CT041 | CLDN18.2 / Gastric | Clinical | N/A | N/A | World-First Solid Tumor |
* Prices are approximate and may vary by hospital and individual patient condition. Contact us for current pricing.
From initial consultation to post-treatment follow-up — we guide you through every step.
Submit your pathology reports, imaging, and treatment history for expert evaluation.
Hematology specialist reviews your case and confirms CAR-T candidacy.
Detailed plan including hospital, physician, timeline, and all-inclusive pricing.
Medical visa invitation, flight booking, airport pickup, and accommodation.
Leukapheresis, manufacturing, infusion, and CRS/ICANS monitoring in hospital.
Long-term monitoring, remote consultations, and coordination with your home physician.
Submit your medical records and our hematology specialists will evaluate your case within 48 hours.
Request Free Assessment →